[go: up one dir, main page]

BR9909027A - Composição hormonal tópica com efeito sistêmico - Google Patents

Composição hormonal tópica com efeito sistêmico

Info

Publication number
BR9909027A
BR9909027A BR9909027-9A BR9909027A BR9909027A BR 9909027 A BR9909027 A BR 9909027A BR 9909027 A BR9909027 A BR 9909027A BR 9909027 A BR9909027 A BR 9909027A
Authority
BR
Brazil
Prior art keywords
systemic
hormonal composition
systemic effect
topical hormonal
topical
Prior art date
Application number
BR9909027-9A
Other languages
English (en)
Inventor
Michel Lanquetin
Jacques Paris
Jean-Louis-Thomas
Original Assignee
Theramex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theramex filed Critical Theramex
Publication of BR9909027A publication Critical patent/BR9909027A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)

Abstract

"COMPOSIçãO HORMONAL TóPICA COM EFEITOSISTêMICO". A invenção refere-se ao campo de químicaterapêutica e mais particularmente à produção de novas formasgalênicas designadas serem aplicadas sobre a pele. Maisespecificamente, ela refere-se a composição hormonal tópica comefeito sistêmico para remediar deficiência de progesterona namulher pré menopausa e como substituto hormonal para a mulherem pós menopausa. A invenção é caracterizada pelo fato decompreender, como princípio ativo, um gestagênico derivado de19-nor progesterona, um carreador para passagem sistêmica dodito princípio ativo selecionado do grupo consistindo em umagnete solubilizante, um agente de promoção de absorção, umagente formador de filme, um agnete de enchimento ou suasmisturas, associados com ou misturados com carreadoresapropriados para produção de uma forma farmacêutica formadorade filme e/ou gelificada.
BR9909027-9A 1998-03-23 1999-03-23 Composição hormonal tópica com efeito sistêmico BR9909027A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9803533A FR2776191B1 (fr) 1998-03-23 1998-03-23 Composition hormonale topique a effet systemique
PCT/FR1999/000680 WO1999048477A1 (fr) 1998-03-23 1999-03-23 Composition hormonale topique a effet systemique

Publications (1)

Publication Number Publication Date
BR9909027A true BR9909027A (pt) 2001-12-11

Family

ID=9524367

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909027-9A BR9909027A (pt) 1998-03-23 1999-03-23 Composição hormonal tópica com efeito sistêmico

Country Status (28)

Country Link
US (1) US20080227763A1 (pt)
EP (1) EP1066030B1 (pt)
JP (1) JP4579411B2 (pt)
KR (1) KR100681322B1 (pt)
CN (1) CN1161102C (pt)
AP (1) AP1343A (pt)
AT (1) ATE353626T1 (pt)
AU (1) AU754490B2 (pt)
BR (1) BR9909027A (pt)
CA (1) CA2324904C (pt)
CY (1) CY1106463T1 (pt)
CZ (1) CZ300484B6 (pt)
DE (1) DE69935135T2 (pt)
DK (1) DK1066030T3 (pt)
ES (1) ES2283106T3 (pt)
FR (1) FR2776191B1 (pt)
HU (1) HU228863B1 (pt)
ID (1) ID27988A (pt)
IL (1) IL138607A0 (pt)
NO (1) NO331222B1 (pt)
NZ (1) NZ507201A (pt)
OA (1) OA11489A (pt)
PL (1) PL204210B1 (pt)
PT (1) PT1066030E (pt)
RU (1) RU2215520C2 (pt)
TR (1) TR200002751T2 (pt)
WO (1) WO1999048477A1 (pt)
ZA (1) ZA200005785B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU767154B2 (en) 1998-11-20 2003-10-30 Skyepharma Canada Inc. Dispersible phospholipid stabilized microparticles
WO2001030356A1 (fr) * 1999-10-25 2001-05-03 Laboratoire Theramex Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
DE10008128A1 (de) * 2000-02-22 2001-08-23 Bayer Ag Endoparasitizide Mittel
KR100452972B1 (ko) * 2000-05-16 2004-10-14 주식회사 삼양사 경피투여용 하이드로젤 조성물
EP1307232B1 (en) 2000-08-03 2007-03-07 Antares Pharma IPL AG Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
FR2814074B1 (fr) * 2000-09-15 2003-03-07 Theramex Nouvelles compositions estro-progestatives topiques a effet systemique
US7803392B2 (en) 2000-12-27 2010-09-28 University Of Kentucky Research Foundation pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules
US7005557B2 (en) * 2001-07-03 2006-02-28 The Procter & Gamble Company Film-forming compositions for protecting skin from body fluids and articles made therefrom
GB0119480D0 (en) 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
DE10146541A1 (de) * 2001-09-21 2003-04-17 Kade Pharma Fab Gmbh Arzneimittel auf Basis von Gestagenen zur dermalen Anwendung
BRPI0414551B8 (pt) 2003-10-10 2021-05-25 Antares Pharma Ipl Ag formulação farmacêutica transdérmica ou transmucosa e método de protelação ou inibição da cristalização de um agente ativo
US7425340B2 (en) 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US7772213B2 (en) 2006-07-27 2010-08-10 Nathan Strick Composition for the treatment of inflammatory conditions
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP2742932A1 (en) * 2012-12-17 2014-06-18 Laboratorios Ojer Pharma S.L. Gel compositions
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
BR112016029338A2 (pt) * 2014-07-29 2017-08-22 Therapeuticsmd Inc creme transdérmico
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
MX2018011705A (es) 2016-04-01 2019-06-10 Therapeuticsmd Inc Composicion farmaceutica de hormona esteroide.
WO2020161771A1 (ja) * 2019-02-04 2020-08-13 マルホ株式会社 皮膚用組成物
GB2597637A (en) * 2020-06-02 2022-02-09 Surfachem Ltd Sanitiser composition
CA3206383A1 (en) * 2021-02-02 2022-08-11 Sangmesh TORNE An aqueous gel composition comprising an ethylcellulose

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1515284A (en) * 1974-05-21 1978-06-21 Gastaud J Pharmaceutical compositions containing progestogens derived from the 17-alpha-hydroxy-19-nor-progesterone series
DE69125855T2 (de) * 1990-06-01 1997-07-31 The Population Council, New York, N.Y. Therapeutisch wirksame, örtliche anwendung von st1435
FR2668945B1 (fr) * 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
JPH05148146A (ja) * 1991-06-20 1993-06-15 Terumo Corp 水溶性ゲル外用剤
JP2960832B2 (ja) * 1992-05-08 1999-10-12 ペルマテック テクノロジー アクチェンゲゼルシャフト エストラジオールの投与システム
FR2695826B1 (fr) * 1992-09-21 1995-01-06 Theramex Nouvelles compositions pharmaceutiques à base de dérivés de nomégestrol et leurs procédés d'obtention.
DE4309830C1 (de) * 1993-03-26 1994-05-05 Lohmann Therapie Syst Lts Wirkstoffpflaster für die Abgabe von Estradiol an die Haut
IL105600A (en) * 1993-05-04 1999-12-31 Allon Blank Pharmaceutical and cosmetic compositions with increased rate of transdermal penetration and antioxidation protection against degradation containing derivatives of thioglycolic and mercaptopropionic acids some such novel compounds and their use
EP0785212A1 (en) * 1996-01-22 1997-07-23 Laboratoire Theramex New 19-nor-pregnene derivatives
EP0785211A1 (en) * 1996-01-22 1997-07-23 Laboratoire Theramex New substituted 19-nor-pregnane derivatives
JP4346696B2 (ja) * 1996-05-28 2009-10-21 久光製薬株式会社 経皮治療用装置
IT1283102B1 (it) * 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele

Also Published As

Publication number Publication date
KR100681322B1 (ko) 2007-02-09
CA2324904A1 (fr) 1999-09-30
AP2000001948A0 (en) 2000-12-31
AU2845199A (en) 1999-10-18
CA2324904C (fr) 2009-03-03
FR2776191A1 (fr) 1999-09-24
NZ507201A (en) 2003-07-25
WO1999048477A1 (fr) 1999-09-30
DE69935135D1 (de) 2007-03-29
PT1066030E (pt) 2007-05-31
OA11489A (fr) 2004-05-08
RU2215520C2 (ru) 2003-11-10
HUP0101579A3 (en) 2002-01-28
JP2002507561A (ja) 2002-03-12
JP4579411B2 (ja) 2010-11-10
ES2283106T3 (es) 2007-10-16
ZA200005785B (en) 2001-06-12
NO20004745L (no) 2000-11-20
DK1066030T3 (da) 2007-06-11
NO20004745D0 (no) 2000-09-22
NO331222B1 (no) 2011-11-07
PL343256A1 (en) 2001-07-30
ID27988A (id) 2001-05-03
TR200002751T2 (tr) 2000-12-21
CZ20003471A3 (cs) 2001-07-11
EP1066030B1 (fr) 2007-02-14
CZ300484B6 (cs) 2009-05-27
IL138607A0 (en) 2001-10-31
FR2776191B1 (fr) 2002-05-31
CN1161102C (zh) 2004-08-11
ATE353626T1 (de) 2007-03-15
HUP0101579A2 (hu) 2001-11-28
PL204210B1 (pl) 2009-12-31
HU228863B1 (en) 2013-06-28
US20080227763A1 (en) 2008-09-18
AP1343A (en) 2004-12-15
EP1066030A1 (fr) 2001-01-10
CN1301146A (zh) 2001-06-27
AU754490B2 (en) 2002-11-21
KR20010042152A (ko) 2001-05-25
HK1038184A1 (en) 2002-03-08
DE69935135T2 (de) 2007-10-31
CY1106463T1 (el) 2012-01-25

Similar Documents

Publication Publication Date Title
BR9909027A (pt) Composição hormonal tópica com efeito sistêmico
BR0107216A (pt) Compostos estroprogestacionais tópicos com efeito sistêmico
BR0016708A (pt) Forma de dosagem de droga baseada em hidrogel
BR0113649A (pt) Processo para aumentar a testosterona e as relacionadas concentrações de esteróide em mulheres
BR0116945A (pt) Uma preparação para prevenção de restenose
Shukla et al. Hepatoprotective activity in the rat of ursolic acid isolated from Eucalyptus hybrid
MY126960A (en) Administration of non-oral androgenic steroids to women
BR9913288A (pt) Composição antioxidante compreendendo acetil l-carnitina e ácido alfa-lipóico
ATE299740T1 (de) Kombination aus einem no-donor und einem antioxidans zur behanndlung sexueller störungen
BR0107535A (pt) Uso de carotenóides e forma de dosagem unitária destes
ATE286718T1 (de) Temperatursensitive liposomale formulierung
DK0836506T3 (da) Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen
BR0113067A (pt) Forma de dosagem de drogas à base de hidrogel
DE60330695D1 (de) Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate
DE69933049D1 (de) Pharmazeutische zusammensetzung und verwendung von rnsaid zur behandlung der entzündung
PT1061929E (pt) Composicao farmaceutica a base de progesterona natural de sintese e de estradiol e processo para a sua preparacao
WO2002058706A3 (en) Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy
BR0208161A (pt) Forma farmacêutica sólida orodispersìvel
BR0013625A (pt) Composição para uso no tratamento de carcinoma hepatocelular
HUP0101005A2 (hu) Szteroid aromatáz gátlót tartalmazó gyógyszer emlőrák megelőzésére és/vagy kezelésére
MEP13808A (en) Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders
BR9307866A (pt) Esteróides estreno como iniciadores neuroquímicos de mudança em funçao hipotalamica humana e composiçoes farmaceuticas relacionadas e processos
PT1135169E (pt) Uso de uma composicao farmaceutica compreendendo um agente anti-canceroso e pelo menos um peptideo
BR0013272A (pt) Uso de uma substância que inibe a produção de e/ou o efeito dos estrogênios, ou de uma composição contendo a citada substância, e, composição cosmética para aplicação tópica
ES2152322T3 (es) Composicion de sulfato de colistina estabilizada.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADO DE INT. CL: A61K 9/06; 31/57; A61P 5/24

Ipc: A61K 9/06 (2008.01), A61K 31/57 (2008.01), A61P 5/

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011.